DLL4 and cancer: Interestingly, a bispecific antibody targeting VEGF and Dll4 (ABL001/NOV1501/TR009), has been recently assessed in a phase 1 clinical trial of heavy chemotherapy or targeted therapy in pre-treated cancer patients, demonstrating higher anti-cancer effects in several human cancer xenografts than the VEGF-targeting antibody (bevacizumab—similar) and the Dll4-targeting monoclonal antibody alone [79].